Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

NCT06015464 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT06015464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06015464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2023
Completion date
July 30, 2025
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large b-cell, diffuse neoplasms by histologic type